This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Non-hodgkin Lymphoma or Hodgkin Lymphoma
and you are
between 18 and 72
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome.

Provided treatments

  • Drug: Sirolimus
  • Drug: Methotrexate
  • Drug: Tacrolimus
  • Drug: Cyclosporine
  • Drug: MMF
Tris trial is registered with FDA with number: NCT00928018. The sponsor of the trial is Dana-Farber Cancer Institute and it is looking for 139 volunteers for the current phase.
Official trial title:
A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma